In less than 36 hours between the evening of Jan. 12 and the morning of Jan. 14, three local life science companies raised a ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its treatment that tunes gene activity within the body. Why it matters: The ...

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...

Tune Therapeutics’ co-founders, from left: Akira Matsuno, chief financial officer; Charles Gersbach; and Fyodor Urnov, who also serves on the startup’s scientific advisory board. (Tune Photos ...

CAMBRIDGE, Mass. - Eterna Therapeutics (NASDAQ:ERNA), a biotechnology company specializing in cell therapies for solid tumors ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the addition of Jerome ...

DURHAM, N.C. & SEATTLE, January 13, 2025--(BUSINESS WIRE)--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New ...

The Durham ID building in downtown Durham, NC holds the North Carolina office of Tune Therapeutics, a growing biotech startup moving into trials. Brian Gordon Launched from a Duke University lab ...

DURHAM, N.C. & SEATTLE, January 13, 2025--(BUSINESS WIRE)--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise ...